0000920465-14-000010.txt : 20140304 0000920465-14-000010.hdr.sgml : 20140304 20140303200645 ACCESSION NUMBER: 0000920465-14-000010 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140303 ITEM INFORMATION: Other Events FILED AS OF DATE: 20140304 DATE AS OF CHANGE: 20140303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 14662338 BUSINESS ADDRESS: STREET 1: 4660 LA JOLLA VILLAGE DRIVE, SUITE 1070 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4660 LA JOLLA VILLAGE DRIVE, SUITE 1070 CITY: SAN DIEGO STATE: CA ZIP: 92122 8-K 1 a8-k2014conversion.htm 8-K 8-K 2014 Conversion
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
_______________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 26, 2014
_______________________

LA JOLLA PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
_______________________

California
0-24274
33-0361285
(State or other jurisdiction of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)


4660 La Jolla Village Drive, Suite 1070, San Diego, California 92122
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (858) 207-4264
_______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))




Item 8.01    Other Events.

On February 26, 2014, La Jolla Pharmaceutical Company (the “Company”) had converted approximately 679 shares of Series C-12 Convertible Preferred Stock, $0.0001 par value per share, into 1,170,716 shares of common stock, $0.0001 par value per share (the “Common Stock”) and converted approximately 184 shares of Series F Convertible Preferred Stock, $0.0001 par value per share, into 52,521 shares of Common Stock. Following these conversions, the Company had a total of 6,059,953 shares of Common Stock issued and outstanding.
As a result each holder of the converted shares owns less than 9.999% of the Company’s issued and outstanding Common Stock.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
   
 
LA JOLLA PHARMACEUTICAL COMPANY
 
 
 
 
Date:
March 3, 2014
By:
/s/    George F. Tidmarsh
 
   
Name:
George F. Tidmarsh, M.D., Ph.D.
 
   
Title:
President and Chief Executive Officer